This approval provides a new non-steroidal, topical treatment option for the millions of Americans living with atopic dermatitis or eczema. Shares of Aurobindo Pharma Ltd ended at ₹1,155.45, down by ₹2.10, or 0.18%, on the BSE today, February 13.
This approval provides a new non-steroidal, topical treatment option for the millions of Americans living with atopic dermatitis or eczema. Shares of Aurobindo Pharma Ltd ended at ₹1,155.45, down by ₹2.10, or 0.18%, on the BSE today, February 13.